These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37221817)

  • 1. Population pharmacokinetic analysis of sparsentan in healthy volunteers and patients with focal segmental glomerulosclerosis.
    Wada R; Kleijn HJ; Zhang L; Chen SC
    CPT Pharmacometrics Syst Pharmacol; 2023 Aug; 12(8):1080-1092. PubMed ID: 37221817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.
    Trachtman H; Nelson P; Adler S; Campbell KN; Chaudhuri A; Derebail VK; Gambaro G; Gesualdo L; Gipson DS; Hogan J; Lieberman K; Marder B; Meyers KE; Mustafa E; Radhakrishnan J; Srivastava T; Stepanians M; Tesar V; Zhdanova O; Komers R;
    J Am Soc Nephrol; 2018 Nov; 29(11):2745-2754. PubMed ID: 30361325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically-based pharmacokinetic model of sparsentan to evaluate drug-drug interaction potential.
    Patel NK; Chen KF; Chen SC; Liu K
    CPT Pharmacometrics Syst Pharmacol; 2024 Feb; 13(2):317-329. PubMed ID: 38041499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sparsentan: A First-in-Class Dual Endothelin and Angiotensin II Receptor Antagonist.
    Chiu AW; Bredenkamp N
    Ann Pharmacother; 2024 Jun; 58(6):645-656. PubMed ID: 37706310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sparsentan: First Approval.
    Syed YY
    Drugs; 2023 Apr; 83(6):563-568. PubMed ID: 37022667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
    Rheault MN; Alpers CE; Barratt J; Bieler S; Canetta P; Chae DW; Coppock G; Diva U; Gesualdo L; Heerspink HJL; Inrig JK; Kirsztajn GM; Kohan D; Komers R; Kooienga LA; Lieberman K; Mercer A; Noronha IL; Perkovic V; Radhakrishnan J; Rote W; Rovin B; Tesar V; Trimarchi H; Tumlin J; Wong MG; Trachtman H;
    N Engl J Med; 2023 Dec; 389(26):2436-2445. PubMed ID: 37921461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety.
    Campbell KN; Gesualdo L; Murphy E; Rheault MN; Srivastava T; Tesar V; Komers R; Trachtman H
    Kidney Med; 2024 Jun; 6(6):100833. PubMed ID: 38831932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis.
    Komers R; Diva U; Inrig JK; Loewen A; Trachtman H; Rote WE
    Kidney Int Rep; 2020 Apr; 5(4):494-502. PubMed ID: 32274453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET).
    Komers R; Gipson DS; Nelson P; Adler S; Srivastava T; Derebail VK; Meyers KE; Pergola P; MacNally ME; Hunt JL; Shih A; Trachtman H
    Kidney Int Rep; 2017 Jul; 2(4):654-664. PubMed ID: 29142983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of protective actions of sparsentan in the kidney: lessons from studies in models of chronic kidney disease.
    Kohan DE; Bedard PW; Jenkinson C; Hendry B; Komers R
    Clin Sci (Lond); 2024 Jun; 138(11):645-662. PubMed ID: 38808486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Multiple Doses of Sparsentan on the Single-Dose Pharmacokinetics of Dapagliflozin: An Open-Label Drug-Drug Interaction Study in Healthy Adults.
    Chen SC; Cai D; Winnett C; Nguyen M; Verma N; Liu K; Preciado P
    Clin Pharmacol Drug Dev; 2023 May; 12(5):535-541. PubMed ID: 36852566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study.
    Trachtman H; Radhakrishnan J; Rheault MN; Alpers CE; Barratt J; Heerspink HJL; Noronha IL; Perkovic V; Rovin B; Trimarchi H; Wong MG; Mercer A; Inrig J; Rote W; Murphy E; Bedard PW; Roth S; Bieler S; Komers R
    Kidney Int Rep; 2024 Apr; 9(4):1020-1030. PubMed ID: 38765567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renoprotective effects of sparsentan: clinical trial evidence in IgA nephropathy and FSGS.
    Wang M
    Nat Rev Nephrol; 2024 Jan; 20(1):6. PubMed ID: 38012264
    [No Abstract]   [Full Text] [Related]  

  • 14. Interventions for focal segmental glomerulosclerosis in adults.
    Hodson EM; Sinha A; Cooper TE
    Cochrane Database Syst Rev; 2022 Feb; 2(2):CD003233. PubMed ID: 35224732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sparsentan is superior to losartan in the gddY mouse model of IgA nephropathy.
    Nagasawa H; Ueda S; Suzuki H; Jenkinson C; Fukao Y; Nakayama M; Otsuka T; Okuma T; Clapper W; Liu K; Nguyen M; Komers R; Suzuki Y
    Nephrol Dial Transplant; 2024 Aug; 39(9):1494-1503. PubMed ID: 38271614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.
    Zahir H; Greenberg J; Shuster D; Hsu C; Watanabe K; LaCreta F
    Clin Pharmacokinet; 2022 Nov; 61(11):1623-1639. PubMed ID: 36264536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sparsentan - Another Arrow in the Quiver for Treatment of FSGS?
    Ingelfinger JR
    N Engl J Med; 2023 Dec; 389(26):2482-2483. PubMed ID: 37921485
    [No Abstract]   [Full Text] [Related]  

  • 18. Implications of Complete Proteinuria Remission at any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial.
    Trachtman H; Diva U; Murphy E; Wang K; Inrig J; Komers R
    Kidney Int Rep; 2023 Oct; 8(10):2017-2028. PubMed ID: 37850006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice.
    Campbell KN; Griffin S; Trachtman H; Geletka R; Wong MG
    Int J Nephrol Renovasc Dis; 2023; 16():281-291. PubMed ID: 38149041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from 10 phase I trials.
    Patel P; Howgate E; Martin P; Carlile DJ; Aarons L; Zhou D
    Br J Clin Pharmacol; 2018 Jan; 84(1):52-63. PubMed ID: 28833380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.